VEGFA and adenomyosis: Second, neutralizing VEGF by bevacizumab suppressed oestrogen-induced angiogenesis in vitro and the implantation of adenomyotic lesions in vivo, suggesting that it may be an appropriate drug for the treatment of adenomyosis.